drugset / Trial / NCT00036933
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Phase 1
Completed
9 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as QS21 use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with QS21 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with QS21 in treating patients who have prostate cancer.
Timeline
- Start
- 2002-03
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUC-2-Globo H-KLH conjugate vaccine | Vaccine | — | Subcutaneous |
| Background | QS-21 | Other / unclassified | — | Subcutaneous |